Cargando…

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression

HER2-positive breast cancers may lose HER2 expression in recurrences and metastases. In this work, we studied cell lines derived from two transgenic mammary tumors driven by human HER2 that showed different dynamics of HER2 status. MamBo89HER2(stable) cell line displayed high and stable HER2 express...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giusti, Veronica, Ruzzi, Francesca, Landuzzi, Lorena, Ianzano, Marianna L., Laranga, Roberta, Nironi, Elena, Scalambra, Laura, Nicoletti, Giordano, De Giovanni, Carla, Olivero, Martina, Arigoni, Maddalena, Calogero, Raffaele, Nanni, Patrizia, Palladini, Arianna, Lollini, Pier-Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590694/ https://www.ncbi.nlm.nih.gov/pubmed/34775465 http://dx.doi.org/10.1038/s41389-021-00360-9

Ejemplares similares

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
por: Landuzzi, Lorena, et al.
Publicado: (2021)

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
por: De Giovanni, Carla, et al.
Publicado: (2014)

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Nanni, Patrizia, et al.
Publicado: (2018)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
por: Palladini, Arianna, et al.
Publicado: (2017)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Prevention and Therapy of Metastatic HER-2(+) Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model
por: De Giovanni, Carla, et al.
Publicado: (2019)

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
por: Ianzano, Marianna L., et al.
Publicado: (2013)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
por: De Giovanni, Carla, et al.
Publicado: (2019)

Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(−/−);Il2rg(−/−) Mice and Treatment with PI3K Inhibitor
por: Nanni, Patrizia, et al.
Publicado: (2012)

Virus-like particle display of HER2 induces potent anti-cancer responses
por: Palladini, Arianna, et al.
Publicado: (2018)

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas
por: Landuzzi, Lorena, et al.
Publicado: (2014)

Cancer immunoprevention: from mice to early clinical trials
por: Palladini, Arianna, et al.
Publicado: (2018)

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice
por: Nanni, Patrizia, et al.
Publicado: (2001)

Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
por: Boggio, Katia, et al.
Publicado: (1998)

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
por: Nanni, Patrizia, et al.
Publicado: (2019)

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
por: De Giovanni, C, et al.
Publicado: (2012)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research
por: Landuzzi, Lorena, et al.
Publicado: (2023)

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017)

Modeling the competition between lung metastases and the immune system using agents
por: Pennisi, Marzio, et al.
Publicado: (2010)

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
por: Bandini, Silvio, et al.
Publicado: (2013)

Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells.
por: Nanni, P., et al.
Publicado: (1996)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET
por: Pantaleo, Maria A., et al.
Publicado: (2010)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
por: Soares, Maria, et al.
Publicado: (2016)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination.
por: Nicoletti, G., et al.
Publicado: (1992)

Developmental Expression of Claudins in the Mammary Gland
por: Baumgartner, Heidi K., et al.
Publicado: (2017)

Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2021)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_bjlh7khdslvh2l27t8cvn28aji